CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2019
2019
Historique:
accepted:
02
04
2019
entrez:
11
9
2020
pubmed:
23
5
2019
medline:
23
5
2019
Statut:
epublish
Résumé
The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent report showing prognostic significance of We investigated the five new Four In this study, we report a composite CD33_PGx6_score using directional genotype scores of
Identifiants
pubmed: 32914031
doi: 10.1200/PO.18.00387
pii: 1800387
pmc: PMC7446480
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : U10 CA180886
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180899
Pays : United States
Informations de copyright
© 2019 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Michael LokenEmployment: Hematologics, Hematologics (I) Leadership: Hematologics, Hematologics (I) Stock and Other Ownership Interests: Hematologics, Hematologics (I) Consulting or Advisory Role: Newlink GeneticsRichard AplencHonoraria: Sigma-Tau Expert Testimony: Wiggin and Dana Travel, Accommodations, Expenses: Sigma-TauIrwin D. BernsteinStock and Other Ownership Interests: Nohla Therapeutics, Lyell Consulting or Advisory Role: Nohla Therapeutics Patents, Royalties, Other Intellectual Property: Multiple patents through Fred Hutchinson Cancer Research Center, share of royalties from Fred Hutchinson Cancer Research CenterAlan S. GamisConsulting or Advisory Role: NovartisJatinder K. LambaPatents. Royalties, Other Intellectual Property: Patent application No. 16/091,720 entitled ‘Biomarkers of Anti-Leukemic Therapy’ No other potential conflicts of interest were reported.
Références
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Blood. 2013 Jun 13;121(24):4854-60
pubmed: 23591789
Leuk Res. 2008 Jun;32(6):845-6
pubmed: 18023867
Leuk Lymphoma. 2019 Sep;60(9):2287-2290
pubmed: 30721105
Clin Cancer Res. 2001 Jun;7(6):1490-6
pubmed: 11410481
J Clin Oncol. 2012 Nov 10;30(32):3924-31
pubmed: 22851554
Clin Cancer Res. 2013 Mar 15;19(6):1620-7
pubmed: 23444229
Leukemia. 2013 Apr;27(4):843-51
pubmed: 23222369
Oncologist. 2018 Sep;23(9):1103-1108
pubmed: 29650683
Lancet. 2012 Apr 21;379(9825):1508-16
pubmed: 22482940
Expert Opin Investig Drugs. 2018 Apr;27(4):339-348
pubmed: 29534618
Blood. 2018 Jan 25;131(4):468-471
pubmed: 29229596
Cancer Res. 1992 Jan 1;52(1):89-94
pubmed: 1530769
J Clin Oncol. 2014 Sep 20;32(27):3021-32
pubmed: 25092781
J Clin Oncol. 1991 Mar;9(3):478-90
pubmed: 1999719
J Clin Oncol. 2017 Aug 10;35(23):2674-2682
pubmed: 28644774
Leukemia. 2013 Jan;27(1):75-81
pubmed: 22964882
Cancer. 2012 Feb 1;118(3):761-9
pubmed: 21766293
J Clin Oncol. 2011 Feb 1;29(4):369-77
pubmed: 21172891
Haematologica. 2016 Jun;101(6):724-31
pubmed: 26921360
J Clin Oncol. 2016 Mar 1;34(7):747-55
pubmed: 26786921
Blood. 2012 Apr 19;119(16):3705-11
pubmed: 22378848
Clin Cancer Res. 2018 Jul 15;24(14):3242-3246
pubmed: 29476018
Curr Treat Options Oncol. 2011 Dec;12(4):329-40
pubmed: 22006038
J Clin Invest. 1987 Apr;79(4):1153-9
pubmed: 3470307
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
Leukemia. 2009 Feb;23(2):402-4
pubmed: 18615103